737eP From complexity to clarity: Development of an Italian triple-negative breast cancer patient journey

very poor.In recent years, trans-arterial approaches have become safe and reliable, diagnostic imaging techniques have been implemented during treatment, embolization materials have improved, and these techniques can now be used to treat breast cancer.The trans-arterial treatment using anti-neoplastic agents and spherical embolic material for primary tumors and axillary lymph node metastases was introduced to control the both lesions.The purpose of this study is to confirm the clinical value of trans-arterial management of LABC.Methods: A total of 31 previously untreated patients with LABC in T3(5) or T4(26) were evaluated retrospectively.A microcatheter was advanced selectively to all branches of the breast tumors and axillary lymph node metastases.Drug distribution was confirmed by CT during selective infusion of contrast agent.The anti-neoplastic agents used were standard drugs for breast cancer treatment.Infusions of anticancer drugs into tumorfeeding arteries were followed by embolization with superabsorbent polymer microspheres.After a month, additional treatments were repeated on demand.The primary endpoint was tumor reduction by RECIST criteria in 1,3,6,12 months.The secondary endpoint was overall survival.Prognostic factors were analyzed. Results:The response rates of primary breast lesions in 1,3,6,12 months were, 19%, 48%, 79%, 70%, respectively.The adverse events which needed any therapies were not found.Local pain, bleeding, and other symptoms were well controlled after the initial treatment.Survival rates in 1 year and 2 years were 87.1% and 67.6%, respectively.Overall survival was 29.7 months. Conclusions:Trans-arterial chemoembolization therapy for LABC is feasible and effective to reduce the tumor burden and to improving symptoms.Consequently, better QOL and improved life expectancy are to be expected.